NO933695D0 - Partikler av biologisk aktive substanser og farmasoeytiskepreparater inneholdene disse - Google Patents

Partikler av biologisk aktive substanser og farmasoeytiskepreparater inneholdene disse

Info

Publication number
NO933695D0
NO933695D0 NO933695A NO933695A NO933695D0 NO 933695 D0 NO933695 D0 NO 933695D0 NO 933695 A NO933695 A NO 933695A NO 933695 A NO933695 A NO 933695A NO 933695 D0 NO933695 D0 NO 933695D0
Authority
NO
Norway
Prior art keywords
particles
biologically active
active substances
pharmaceutical preparations
preparations containing
Prior art date
Application number
NO933695A
Other languages
English (en)
Norwegian (no)
Inventor
Peter Gassmann
Heinz Sucker
Original Assignee
Sandoz Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27202407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO933695(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz Ltd filed Critical Sandoz Ltd
Publication of NO933695D0 publication Critical patent/NO933695D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Colloid Chemistry (AREA)
NO933695A 1991-04-19 1993-10-14 Partikler av biologisk aktive substanser og farmasoeytiskepreparater inneholdene disse NO933695D0 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4112854 1991-04-19
DE4113016 1991-04-20
DE4113343 1991-04-24
PCT/EP1992/000862 WO1992018105A1 (fr) 1991-04-19 1992-04-16 Perfectionnements apportes aux compositions pharmaceutiques

Publications (1)

Publication Number Publication Date
NO933695D0 true NO933695D0 (no) 1993-10-14

Family

ID=27202407

Family Applications (1)

Application Number Title Priority Date Filing Date
NO933695A NO933695D0 (no) 1991-04-19 1993-10-14 Partikler av biologisk aktive substanser og farmasoeytiskepreparater inneholdene disse

Country Status (16)

Country Link
EP (1) EP0580690B2 (fr)
JP (1) JP3695754B2 (fr)
AT (1) AT410896B (fr)
AU (1) AU1577992A (fr)
CA (1) CA2108018C (fr)
DE (1) DE4291156T1 (fr)
ES (1) ES2069995T5 (fr)
FR (1) FR2675382B1 (fr)
GB (1) GB2269536B (fr)
IE (1) IE921230A1 (fr)
IL (1) IL101635A0 (fr)
IT (1) IT1254323B (fr)
MX (1) MX9201782A (fr)
NO (1) NO933695D0 (fr)
WO (1) WO1992018105A1 (fr)
ZA (1) ZA922834B (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
EP2283821A1 (fr) * 1993-11-19 2011-02-16 Alkermes, Inc. Préparation des microparticules biodégradables contenant un agent biologiquement actif
WO1996025918A1 (fr) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols contenant des dispersions de nanoparticules
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
CA2326456C (fr) 1998-03-30 2008-12-23 Rtp Pharma Inc. Composition et procede de preparation de microparticules de substances insolubles dans l'eau
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DE19821951A1 (de) * 1998-05-15 1999-11-18 Basf Ag Cyclosporin-Zubereitungen
EP1079808B1 (fr) 1998-05-29 2004-02-11 Skyepharma Canada Inc. Compositions de microparticules a protection thermique et procede de sterilisation a la vapeur apres conditionnement
US7939105B2 (en) 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US7008644B2 (en) * 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
CA2669392C (fr) 2006-11-17 2016-05-10 Abbott Gmbh & Co. Kg Nanocristaux pour une utilisation dans des formulations cosmetiques topiques et leur procede de fabrication
WO2008066899A2 (fr) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Formulations de nanoparticules et procédés de préparation et d'utilisation de celles-ci
HU230862B1 (hu) 2008-04-28 2018-10-29 DARHOLDING Vagyonkezelő Kft Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
GB201410869D0 (en) * 2014-06-18 2014-07-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontal disease
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
AU2016338672A1 (en) 2015-10-16 2018-04-12 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
EP4233861A3 (fr) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions pour le traitement du tremblement essentiel
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CN114728012A (zh) 2019-08-05 2022-07-08 马瑞纳斯制药公司 用于治疗癫痫持续状态的加奈索酮
CN114828889B (zh) 2019-12-06 2025-02-14 马瑞纳斯制药公司 用于治疗结节性硬化症的加奈索酮
JP7804312B2 (ja) * 2020-08-07 2026-01-22 国立大学法人信州大学 リポソームおよびその製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1532993A (en) * 1975-03-07 1978-11-22 Beecham Group Ltd Injectable antibiotic compositions
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
CA1282405C (fr) * 1984-05-21 1991-04-02 Michael R. Violante Methode pour produire des particules dimensionnellement uniformes a partir des composes organiques insolubles dans l'eau
US5002940A (en) * 1984-11-06 1991-03-26 Ciba-Geigy Corporation Solid drug formulations and stable suspensions
CH673395A5 (fr) * 1987-01-30 1990-03-15 Ciba Geigy Ag
CA1323306C (fr) * 1987-03-05 1993-10-19 Mircea C. Popescu Preparation comprenant une solution lipidique et un agent pharmacologique
US4963362A (en) † 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
BE1003009A5 (fr) † 1989-02-09 1991-10-22 Sandoz Sa Nouvelles compositions pharmaceutiques a base de cyclosporines.

Also Published As

Publication number Publication date
ATA901092A (de) 2003-01-15
GB2269536A (en) 1994-02-16
JPH06506926A (ja) 1994-08-04
ES2069995T5 (es) 2000-11-16
GB2269536B (en) 1995-05-10
CA2108018A1 (fr) 1992-10-20
EP0580690B1 (fr) 1995-03-15
DE4291156T1 (de) 1994-10-20
EP0580690A1 (fr) 1994-02-02
ITRM920281A1 (it) 1993-10-16
CA2108018C (fr) 2003-04-15
ES2069995T3 (es) 1995-05-16
AT410896B (de) 2003-08-25
WO1992018105A1 (fr) 1992-10-29
GB9319585D0 (en) 1993-12-15
ITRM920281A0 (it) 1992-04-16
ZA922834B (en) 1993-10-18
JP3695754B2 (ja) 2005-09-14
FR2675382B1 (fr) 1995-05-12
AU1577992A (en) 1992-11-17
FR2675382A1 (fr) 1992-10-23
IL101635A0 (en) 1992-12-30
EP0580690B2 (fr) 2000-09-13
IE921230A1 (en) 1992-10-21
IT1254323B (it) 1995-09-14
MX9201782A (es) 1992-10-01

Similar Documents

Publication Publication Date Title
DK108388A (da) Piperazinylalkylheterocycliske forbindelser og farmaceutiske praeparater indeholdende disse
NO943511L (no) Farmasöytiske preparater og anvendelse derav
ATA901092A (de) Teilchen enthaltend biologisch aktives peptid
NO964758D0 (no) Anvendelse av von Willebrand-faktor og farmasöytiske preparater
NO981241D0 (no) Heteroarylsubstituerte akryloylguanidinderivater og farmasöytiske preparater inneholdende disse
DK287188D0 (da) Cephalosporinforbindelser og farmaceutisk praeparat deraf
DK78888A (da) Arylpiperazinylalkylenphenyl-heterocycliske forbindelser og farmaceutiske praeparater indeholdende disse
ATE281166T1 (de) Tizoxanide und/oder nitazoxanide enthaltende pharmazeutische zubereitungen
NO924528L (no) Derivater av humant gallesalt-stimulert lipase og farmasoeytiske sammensetninger som inneholder disse
DK160944C (da) Modificerede beta2-mikroglobuliner og farmaceutiske praeparater indeholdende disse
DK269289A (da) Cyklopentanderivater og farmaceutiske praeparater indeholdende saadanne forbindelser
DK0863878T3 (da) Cycliske nitroner og farmaceutiske præparater indeholdende disse
DK21785A (da) Dihydropyridinforbindelser og farmaceutiske praeparater indeholdende disse
DK4487A (da) Heterocycliske forbindelser og farmaceutiske praeparater indeholdende disse
NO305943B1 (no) Klorfluoretersammensetninger og preparater av disse
DK81185A (da) Carboxicam-enolester-forbindelser og farmaceutiske praeparater indeholdende disse
DK130890A (da) Peptider og farmaceutiske midler indeholdende disse
DE69532578D1 (de) NEUARTIGE GnRH - ANALOGE MIT ANTITUMORALEN EFFEKTEN UND SIE ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN
ZA951789B (en) Pharmaceutical materials and methods of administration
NO179514C (no) Sykliske nitroner og farmasöytisk preparat inneholdende disse
DK488688A (da) Azolidindion-derivater og farmaceutiske praeparater indeholdende disse
DK40292A (da) Dibenzofurancarboxamider og farmaceutiske praeparater indeholdende disse
NO179907C (no) Benzokinoksaliner og farmasöytiske preparater inneholdende de samme
DK547288D0 (da) 5-substituerede-3-phenyl-3-(1h-imidazol-1-ylmethyl)-2-methylisoxazolidiner og farmaceutiske praeparater indeholdende disse
DK162089C (da) 1-phenoxy-3-hydroxyindolylalkylamino-2-propanoler og farmaceutiske praeparater indeholdende disse